


67$7,67,&$/$1$/<6,63/$1



6WXG\7LWOH $0XOWLFHQWHU5DQGRPL]HG'RXEOHEOLQG3ODFHERFRQWUROOHG
3KDVH6WXG\WR(YDOXDWHWKH(IILFDF\DQG6DIHW\RI&\FOR =LQ
3DWLHQWVZLWK2EHVH7\SH'LDEHWHV
 
3KDVH 
3URWRFRO1XPEHU 103&<=3
3URWRFRO9HUVLRQ'DWH 9HUVLRQ'HFHPEHU
6$39HUVLRQ'DWH 9HUVLRQ2FWREHU
$XWKRUV +\XQ-L.LP
3UHSDUHG)RU 1RY0HWD3KDUPD&R/WG

&21),'(17,$/$1'35235,(7$5<,1)250$7,21

NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 3 16 October 2017  Document Version History 
 
Version Date Author Description of Changes  
1.0 21 June 2017  Hyun Ji Kim  Initial version  
1.1 29 August 2017  Hyun Ji Kim  Modified the following by sponsor request.  
1. Added exploratory efficacy analysis for TAFGC . 
2. Added paired t -test (or Wilcoxon signed -rank test ) to 
    analysis the change of efficacy endpoints within each group.  
3. Deleted Analysis for unexpected adverse events . 
1.2 16 October 2017  Hyun Ji Kim  Modified the following by sponsor request.  
1. Added 1 exploratory efficacy endpoint  â€“ BMI.  
2. Added exploratory efficacy analyses for BMI.  
3. Updated calculation for TAFGC.  
4. Added sponsor defined  definitions for Hypoglycemia and  
    Hyperglycemia  
5. Added section for Subgroup Analysis.  
6. Added section for Post -hoc Analysis.  
 
  
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 4 16 October 2017  Table of Abbreviations 
 
Abbreviation  Description  
AE Adverse Event  
ADDQoL  Audit of Diabetes -Dependent Quality of Life  
BMI  Body Mass Index  
BP Blood Pressure  
BSA  Bio-Statistics Associate  
BSM Bio-statistics Manager  
BW Body Weight  
cGMP  Current Good Manufacturing Practice  
CHP  Cyclo (His -pro) 
CRO   Contract Research Organization  
CTCAE  Common Terminology Criteria for Adverse Events  
Cyclo  Cyclic dipeptide  
DBMS  Database Management System  
DM Diabetes Mellitus  
DPP Dipeptidyl Peptidase  
DW Distilled Water  
eCRF  Electronic Case Report Form  
EAS  Efficacy Analysis Set  
EDC  Electronic Data Capture  
FAS Full Analysis Set  
FDA  Food and Drug Administration  
FPG Fasting Plasma Glucose  
GCP  Good Clinical Practice  
G-K Goto -Kakizaki  
GLP  Good Laboratory Practice  
GLP -1 Glucagon -like protein -1 
GLUT -4 Glucose transporter -4 
GMP  Good Manufacturing Practice  
HbA1c  Hemoglobin A1c  
hCG  human chorionic gonadotropin  
IB Investigator â€Ÿs Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IDE Insulin Degrading Enzyme  
IEC Independent Ethics Committee  
IP Investigational Product  
IRB Institutional Review Board  
LOCF  Last Observation Carried Forward  
MedDRA  Medical Dictionary for Regulatory Activities  
MsSQL Microsoft Structured Query Language  
NIDDM  Non-insulin -dependent Diabetes Mellitus  
ODBC  Open Database Connectivity  
OGTT  Oral Glucose Tolerance Test  
PT Preferred Term  
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 5 16 October 2017  SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SD Standard Deviation  
S-D Sprague -Dawley 
SEM  Standard Error of the Mean  
SMC  Safety Monitoring Committee  
SOC  System Organ Class  
SOP Standard Operating Procedure  
TAFGC  Three -hour-area-average Above Fasting Glucose Concentration  
TSH Thyroid Stimulating Hormone  
T3 Triiodothyronine  
T4 Thyroxine  
WHODRUG  World Health Organization Drug  
  
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 6 16 October 2017  Table of Contents 
DOCUMENT VERSION HISTORY ...............................................................................................................3 
TABLE OF ABBREVIATIO NS .......................................................................................................................4 
TABL
E OF CONTENTS ..................................................................................................................................6 
1. INTRO
DUCTION ......................................................................................................................................8 
2. STUDY OBJECTIVE(S) ...........................................................................................................................8 
2.1  Primary Objective ..............................................................................................................................8 
2.2  Secondary Objective ..........................................................................................................................8 
3. STUDY OVERVIEW.................................................................................................................................8 
3.1  Study Design ......................................................................................................................................8 
3.1.1  Overall Study Design ................................................................................................................................  8 
3.1.2  Schedule of Assessment ............................................................................................................................  9 
3.2 Study Population ..............................................................................................................................10 
3.2.1  Inclusion Criteria .................................................................................................................................... 10 
3.2.2  Exclusion Criteria ................................................................................................................................... 10 
3.3 Sample Size Considerations .............................................................................................................11 
3.4 Randomization and Blinding ...........................................................................................................11 
3.4.1  Randomization ........................................................................................................................................ 11 
3.4.2  Blinding .................................................................................................................................................. 12 
4. STUDY ENDPOINTS AND COVARI ATES .........................................................................................12 
4.1 Primary Endpoints ...........................................................................................................................12 
4.2 Secondary Endpoints .......................................................................................................................12 
4.3 Exploratory Endpoints .....................................................................................................................12 
4.4 Safe
ty Endpoints ..............................................................................................................................13 
4.5 Cyclo (His-pro) (CHP) Concentration Evaluation ...........................................................................13 
5. HYPOTHESES .........................................................................................................................................13 
6. DE
FINITIONS .........................................................................................................................................13 
7. AN
ALYSIS SUBSETS .............................................................................................................................14 
7.1 Full An
alysis Set ..............................................................................................................................14 
7.2 Efficacy Analysis Set .......................................................................................................................15 
7.3 Per Protocol Set ................................................................................................................................15 
7.4 Safety Analysis Set ..........................................................................................................................15 
8. INTERIM ANALYSIS.............................................................................................................................16 
9. DATA SCREENING AND ACCPET ANCE .........................................................................................16 
9.1 General Principles ............................................................................................................................16 
9.2 Data Handling and Electronic Transfer of Data ...............................................................................16  
9.3 Handling of Missing and Incomplete Data ......................................................................................16 
9.3.1  Missing and Incomplete Dates ................................................................................................................ 16 
9.3.2  Missing Baseline Evaluation ................................................................................................................... 17 
9.3.3  Missing Post-Baseline Evaluation .......................................................................................................... 17 
9.3.4  Handling of Repeated Laboratory Test Results ......................................................................................  17 
9.4 Handling of Early Termination ........................................................................................................17 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 7 16 October 2017  9.5 Outliers Detection ............................................................................................................................18 
9.6 Bias Detection ..................................................................................................................................19 
9.7 Distributional Characteristics ...........................................................................................................19 
9.8 Va
lidation of Statistical Analyses ....................................................................................................19 
10. STATISTICAL ANALYSES ...................................................................................................................19 
10.1  General Principles ............................................................................................................................19 
10.2  Subject Disposition ..........................................................................................................................20 
10.3  Protocol Deviations ..........................................................................................................................20 
10.4  Demographic and Baseline Characteristics ......................................................................................20 
10.4.1  Demographic Characteristics .................................................................................................................. 20 
10.4.2  Medical History ...................................................................................................................................... 21 
10.4.3  Concomitant Medications .......................................................................................................................  21 
10.4.4  Efficacy Variables at Baseline ................................................................................................................ 21 
10.5  Efficacy Analyses ............................................................................................................................21 
10.5.1  Primary Efficacy Analyses ..................................................................................................................... 23 
10.5.2  Secondary Efficacy Analyses ................................................................................................................. 24 
10.5.3  Exploratory Efficacy Analyses ............................................................................................................... 25 
10.6  Safety Analyses ................................................................................................................................26 
10.6.1  Adverse Events ....................................................................................................................................... 26 
10.6.2  Laboratory Test Results ..........................................................................................................................  28 
10.6.3  Vital Signs .............................................................................................................................................. 28 
10.6.4  Physical Examination and 12-lead ECG ................................................................................................ . 28 
10.6.5  Exposure to IP ......................................................................................................................................... 28 
10.6.6  Concomitant Medication Use ................................................................................................................. 29 
10.7  CHP Concentration Analysis ...........................................................................................................29 
10.8  Subgroup Analysis ...........................................................................................................................29 
10.9  Post-hoc Analysis .............................................................................................................................29 
11. REPORTING CONVENTIONS .............................................................................................................29 
12. ADJUSTED STATISTICAL ANALYSIS METHOD ..........................................................................30 
13. CH
ANGES IN THE STATISTICAL ANALYSIS FROM THE PROTOCOL ..................................30 
14. REFERENCES .........................................................................................................................................33 
 
  
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 8 16 October 2017  1. INTRODUCTION 
 
This Statistical Analysis Plan (SAP) is developed to guide the details of the statistical analysis method of the 
phase 2 study to evaluate the efficacy and safety of Cyclo-Z in patients with obese type 2 diabetes. The SAP 
includes detailed definitions of the populations to be analyzed, the subject characteristics and the efficacy and 
safety endpoints, as well as the specific statistical analysis methods to be performed. 
 
2. STUDY OBJECTIVE(S) 
 
2.1  Primary Objective 
 
The primary objective is to assess the dose-dependent efficacy of Cyclo-Z for the treatment of subjects with 
obese type 2 diabetes. 
 
2.2  Secondary Objective 
 
The secondary objective is to assess the safety of Cyclo-Z in the treatment of subjects with obese type 2 
diabetes. 
 
3. STUDY OVERVIEW  
 
3.1  Study Design 
3.1.1 Overall Study Design 
 
This is a double-blind, randomized, placebo-controlled, parallel-group comparison study to evaluate the 
efficacy and safety of Cyclo-Z vs. placebo in adult subjects with obese type 2 diabetes. Up to four sites may 
be utilized in the United States so that a total of 80 subjects (a potential 20% screening failure rate) may be 
screened for total 16-week study period (2 weeks for screening, 12 weeks for treatment, and 2 weeks for 
safety follow-up). 
 
Subjects who meet preliminary inclusion and exclusion criteria at Screening will undergo a 2-week 
assessment period of record-keeping compliance. Subjects will be asked to record daily blood glucose values 
(fasting before breakfast and two hours after dinner) and study medication adherence throughout study 
participation. 
 
Sixty-four (64) qualified subjects will be assigned randomly to either the placebo arm or to one of the three 
treatment groups requiring the oral intake of a single gel capsule of Cyclo-Z or placebo once daily before 
bedtime for 12 consecutive weeks. 
 
Refer to the schedule of assessment of Section 3.1.2  for a display of all assessments to be conducted. All 
visits are to be scheduled according to their time from the randomization visit (Visit 2).  
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 9 16 October 2017  3.1.2 Schedule of Assessment 
 Screening  Treatment Period  Follow-
up 
Study Visits 1) V1 V2 V3 V4 V5 V6 V7 V8 V9 
Screen 
(Week -2) Baseline 
(Week 0) Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Week 14 
Informed  Consent X         
Inclusion/Exclusion Criteria  X X        
Demographic (including 
height) X         
Medical/Medication History  X         
Physical Examination  X X  X  X  X  
Vital Signs and Body 
Weight  X X X X X X X X X 
12-lead ECG  X       X  
Blood Sampling for serum 
chemistry, hematology, 
FPG, HbA1c, hCG, TSH, 
T3, and T4 2) X X  X  X  X  
Blood Sampling for zinc, 
insulin, adiponectin, C -
peptide, leptin, glucagon, 
[CHP in a subset of  
subjects 3)]  X  X  X  X  
Urine Sampling for glucose, 
microalbumin, copper, and 
zinc   X  X  X  X  
Dispense and Review  
Daily Log  X X X X X X X X  
Dispense and Review 
Medications   X X X X X X X  
Waist Circumference   X  X  X  X  
OGTT 4)   X      X  
ADDQoL Questionnaire   X      X  
Review of Adverse Event 
and Concomitant 
Medication 5)  X X X X X X X X 
1)  Visits 3 to 8 have Â±3 day visit window and Visit 9 has +7 day visit window. 
2) Serum chemistry, hematology: Weeks -2, 0, 4, 8, and 12 
         HbA1c: Weeks -2, 0, 4, 8, and 12 
         FPG: Weeks 0, 4, 8, and 12 
         TSH, T3, T4: Weeks 0 and 12  
         Serum hCG (pregnancy): Weeks -2 and 12 
3) CHP levels may be analyzed in a subset of subjects if residual serum and/or plasma samples are available after  
         completion of protocol-required tests. 
4)  Subjects will be advised to maintain similar exercise and eating habits 3 days prior to the OGTT. Each subject will be 
instructed not to take his or her usual oral medications or insulin injection and food at least 12 hours before coming to the 
clinical site between 7:00 am and 8:30 am for an OGTT. Each subject will be allowed to drink only water during the 12-
hour fasting period prior to the OGTT and advised not to consume any food. Initial blood will be drawn (15 min prior to 
OGTT) for serum chemical analysis. The subject will then consume a glucose solution (75 g), followed by one drop of 
blood drawn for glucose measurements with a glucometer at 0, 0.5, 1.0, 1.5, 2.0, 2.5 and 3 h in the clinical site. 
5)  Assess hypoglycemic & hyperglycemic episodes at Visits 2 to 8 only. 
  
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 10 16 October 2017  3.2 Study Population 
3.2.1 Inclusion Criteria 
 
To be enrolled in the study, a subject must meet all of the following criteria: 
 
1) Males or females aged 18 or older. 
2) Subjects diagnosed with type 2 diabetes mellitus according to the American Diabetes Association (ADA) 
criteria. 
3) Subjects treated with stable doses of insulin and/or other hypoglycemic agent(s) for type 2 diabetes 
mellitus for at least 2 months prior to randomization. 
4) Subjects whose fasting blood glucose levels are reasonably stable for at least 2 months prior to 
randomization and during the 2-week screening period. Stable glucose levels are defined based on the fact 
that the study subjects did not change the dose and/or type of insulin injection and/or other hypoglycemic 
agent(s) during the last 2 months and during the 2-week screening period to adjust blood glucose. 
5) Subjects who have Hemoglobin A1c levels of 7.5 to 10.0 % at Screening. 
6) Subjects whose BMI is 30 or above. 
7) Subjects who can give written informed consent. 
 
3.2.2 Exclusion Criteria 
 
A subject must not be enrolled in the study if any of the following criteria are met: 
 
1) Subjects who have any DM-related end-organ damages.  
2) Subjects who have a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma. 
3) Subjects who have any disease likely to limit life span and/or increase risks of interventions such as: 
â€¢ Carotid B-mode ultrasound test results indicating clinically significant stenosis in the common carotid 
arteries requiring intervention by angioplasty or resection. 
â€¢ Cancer treatment in the past 5 years, with the exception of cancers which have been cured, and carry 
a good prognosis. 
â€¢ Infectious disease: HIV positivity, active tuberculosis, or pneumonia. 
4) Subjects who have any of the following conditions related to cardiovascular disease: 
â€¢ Hospitalization for the treatment of heart disease in the past 12 months. 
â€¢ New York Heart Association Functional Class > 2. 
â€¢ Left Bundle branch block on ECG at Screening. 
â€¢ Third degree atrioventricular block on ECG at Screening. 
â€¢ Uncontrolled hypertension with average systolic blood pressure of > 160 mmHg or diastolic blood 
pressure > 95 mmHg at Screening and Baseline. 
â€¢ Pulse rate > 95 beats per minute at Screening and Baseline. 
â€¢ Stroke or transient ischemic attack in the past 12 months. 
5) Subjects who have any of the following conditions related to gastrointestinal disease: 
â€¢ Chronic hepatitis or cirrhosis. 
â€¢ Episode of alcoholic hepatitis or alcoholic pancreatitis in the past 2 months. 
â€¢ Inflammatory bowel disease requiring treatment in the past 12 months. 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 11 16 October 2017  â€¢ Significant abdominal surgery (e.g., gastrectomy, gastric bypass) in the past 2 months. 
6) Subjects who have serum creatinine > 1.5 mg/dL for male or > 1.4 mg/dL for female. 
7) Subjects who have chronic obstructive airway disease or asthma requiring daily therapy or home use 
oxygen. 
8) Subjects who have hematocrit < 36.0% for male or < 33.0% for female. 
9) Subjects who have any of the following conditions or behaviors likely to affect the conduct of the study: 
â€¢ Weight loss of > 10% in the past 6 months. 
â€¢ Unable to walk without assisted device. 
â€¢ Major psychiatric disorder which would impede conduct of the research. 
â€¢ Excessive alcohol intake (i.e., more than 2 drinks/day). 
10) Subjects who take any of the following medications: 
â€¢ Psychoactive agents such as monoamine oxidase inhibitors and antidepressants (e.g., lithium, Prozac, 
Zoloft, Serzone, Paxil, Effexor). 
â€¢ Any other medications that may pose harm to the subject. 
11) Female subjects who have a positive serum pregnancy test at Screening, plan a pregnancy during study 
period, or are breast feeding.  
12) Female subjects who donâ€Ÿt meet any of the following criteria: 
â€¢ Surgically sterile (i.e., have had bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) at 
least 6 months before randomization.  
â€¢ Post-menopausal for at least 12 months prior to Screening. 
â€¢ If sexually active, they should use oral contraceptives, double barrier contraception (e.g., condom 
with spermicide), intrauterine device, or other methods approved by the Sponsor. 
 
3.3 Sample Size Considerations 
 
This is a Phase 2 clinical trial to evaluate safety and explore the potential efficacy of the study drug. Therefore, 
the number of subjects was not based on formal statistical power considerations. In this clinical trial, a total of 
64 subjects was deemed sufficient and will be enrolled and randomly assigned to be administered with 1 of 3 
dose levels of Cyclo-Z or placebo. 
 
3.4 Randomization and Blinding 
3.4.1 Randomization  
 
At Visit 2 (Week 0), subjects who meet the inclusion/exclusion criteria will be randomly assigned to receive 
placebo or 1 of 3 doses of Cyclo-Z in accordance with the randomization code, which will be generated by 
other Bio-statistics associate (BSA) at Medihelpline rather than the BSA in charge. Specifically, the subjects 
will be randomly assigned in a 1:1:1:1 ratio to the following: 
 
â€¢ Dose A: Cyclo-Z containing 23 mg zinc plus 3 mg CHP â€“ 16 subjects 
â€¢ Dose B
: Cyclo-Z containing 23 mg zinc plus 9 mg CHP â€“ 16 subjects 
â€¢ Dose C
: Cyclo-Z containing 23 mg zinc plus 15 mg CHP â€“ 16 subjects 
â€¢ Dose D
: Placebo â€“ 16 subjects 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 12 16 October 2017  3.4.2 Blinding  
 
As this is a double-blind study, blinding of the drug contents from the subjects, Investigator, and other study 
personnel at each site is necessary. The subject will be assigned with an identification number at Visit 2 
which will remain with the subject throughout the study. 
 
A code-break document including the randomization code information will be retained by each site and can 
be opened, revealing the randomization information, for emergency purposes only. The Investigator should 
note that the occurrence of a SAE should not routinely precipitate immediate unblinding. An attempt to 
contact the Sponsor must be made prior to unblinding. If unblinding occurs, the study medication for the 
subject must be discontinued; a written explanation on the relevant form must be prepared immediately. 
 
4. STUDY ENDPOINTS AND COVARIATES 
 
4.1 Primary Endpoints 
 
The primary clinical efficacy variables used to evaluate the efficacy of Cyclo-Z are: 
 
â€¢ Change of HbA1c level from baseline at Week 12  
â€¢ Change of body weight (BW) from baseline at Week 12 
 
4.2 Secondary Endpoints 
 
The secondary clinical efficacy variables used to evaluate the efficacy of Cyclo-Z are: 
 
â€¢ Change of fasting plasma glucose (FPG) level from baseline at Week 12 
â€¢ Proportion of subjects achieving HbA1c goal of < 7.0% at Week 12 
â€¢ Proportion of subjects achieving HbA1c goal of < 6.5% at Week 12 
â€¢ Change in waist circumference from baseline at Week 12 
â€¢ Change of postprandial (2 hours after dinner) blood glucose level from baseline at Week 12 
â€¢ Change of OGTT from baseline at Week 12 
â€¢ Change of score in Audit of Diabetes-Dependent Quality of Life (ADDQoL) Questionnaire from baseline 
at Week 12 
 
4.3 Exploratory Endpoints 
 
In addition to the primary and secondary endpoints, the following exploratory efficacy variables will be 
separately evaluated for the change from baseline at Week 12: 
 
â€¢ Thyroid Function Test: Thyroid Stimulating Hormone (TSH), Triiodothyronine (T3) and Thyroxine (T4) 
â€¢ Serum Parameters: zinc, insulin, adiponectin, C-peptide, leptin and glucagon 
â€¢ Urine Parameters: zinc, glucose, microalbumin and copper 
â€¢ Three-hour-area-average Above Fasting Glucose Concentration (TAFGC) 
â€¢ Body Mass Index (BMI) 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 13 16 October 2017  4.4 Safety Endpoints 
 
The following safety parameters will be evaluated for the change from baseline assessment: 
 
â€¢ Blood samples for complete laboratory evaluation 
â€¢ ECG evaluation 
â€¢ Physical examination 
â€¢ Vital signs 
â€¢ Adverse events 
â€¢ Episodes of hypoglycemia and hyperglycemia 
 
4.5 Cyclo (His-pro) ( CHP ) Concentration Evaluation 
 
In a subset of subjects where residual serum and/or plasma are available after completion of study-required 
tests, CHP levels in blood may be measured for the change from baseline. 
 
5. HYPOTHESES 
 
The primary objective is to assess the dose-dependent efficacy of Cyclo-Z for the treatment of subjects with 
obese type 2 diabetes. The hypothesis of this study is set as follows. 
 
The dose-dependent efficacy of Cyclo-Z will be demonstrated by identifying statistically significant 
difference in the change of HbA1c level and BW from baseline at Week 12 in Dose A, B, C, and D using one-
way analysis of variance (ANOVA) methods. Specifically, all three experimental groups will be compared to 
the control group on the change: Dose A vs. D, B vs. D, and C vs. D. 
 
                
          
 
   the mean of the primary clinical efficacy variables by each of the four dose groups 
 
6. DE
FINITIONS  
 
â€¢ Baseline  is defined as the last non-missing measurement taken on Week 0.  
 
â€¢ Study day 1  is defined as the first IP dose date. For subjects who are randomized but not dosed after 
randomization, the study day 1 is defined as the date of randomization. 
 
â€¢ Study day is defined as the number of days from study day 1. 
 
Before study day 1:  study day = (date of interest â€“ date of study day 1) 
On or a
fter study day 1:  study day = (date of interest â€“ date of study day 1) + 1 
 
Therefore, the day prior to study day 1 is -1. 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 14 16 October 2017   
â€¢ Study drug exposure day  is defined as the number of days that subjects were on the study drug. 
 
â€¢ Age (years)  is calculated as follows, and is rounded down to an integer. 
 
                                          
       
 
â€¢ Diabetes disease period (years)  is calculated as follows, and is rounded down to an integer. 
 
                                                            
       
 
*If the month and day of date of diagnosis are unknown, it will be converted into January, first day. 
 
â€¢ OGTT  of secondary endpoint is used glucose value at 2 hour after glucose intake. 
 
â€¢ TAFGC  is calculated as follows: 
 
      âˆ‘[                 ( )                                            ]  
   
                                   
 
â€¢ BMI (kg/m2) is calculated as follows: 
 
                (  )
       ( )        ( ) 
 
â€¢ Compliance (%)  is calculated as follows: 
 
                                   
                                                     
 
*By visit:              ( )              (   ) , where n= 3, 4, 5, 6, 7, and 8 
  Overall: âˆ‘(             ( )              (   ))  , where n= 3, 4, 5, 6, 7, and 8 
 
7. ANALYSIS SUBSETS 
 
This study is planned to analy ze in analysis subsets of four groups : Full Analysis Set , Efficacy Analysis Set , 
Per Protocol Set, and Safety Analysis Set. For efficacy analysis, the Efficacy Analysis Set will be considered 
primar ily and the Per Protocol Set will be considered as supportive. The Safety Analysis Set will be used in 
the safety analysis. 
 
7.1 Full Analysis Set  
 
The Full Analysis Set (FAS) includes all subjects who were randomized in the study. Subjects will be 
analyzed according to their randomized treatment, regardless of the treatment received. Tabulations of subject 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 15 16 October 2017  enrollment by site, subject disposition, analysis subsets, demographic and baseline characteristics including 
diabetes disease, past and present medical history, concomitant medication, and protocol deviations including 
major protocol deviations will utilize this analysis set. 
 
7.2 Efficacy Analysis Set  
 
The Efficacy Analysis Set (EAS) will be used to carry out the efficacy analyses of efficacy endpoints, which 
is a subset of the FAS consisting of subjects who received at least one dose of study medication and who had 
baseline and any post-baseline efficacy data. Subjects will be analyzed according to their randomized 
treatment, regardless of the treatment received. Analyses for efficacy endpoints will utilize this analysis set. 
  
7.3 Per Pr
otocol Set  
 
All subjects valid for EAS who meet ALL the following criteria will be â€žvalid per protocolâ€Ÿ (also called â€žvalid 
for efficacyâ€Ÿ): 
 
â€¢ Complete at least 2 weeks of treatment after randomization. 
â€¢ Have both baseline and at least 2 weeks of efficacy data. 
â€¢ Subject did not have any significant violation after randomization. 
 
Major protocol deviations that will potentially impact the primary analysis of efficacy endpoints at Week12 or 
violate GCP at site will be discussed and decided prior to the database lock and will be applied in per protocol 
analysis: 
 
The following cases  are excluded from the P er Protocol Set : 
 
â€¢ Informed consent was not provided 
â€¢ Subjects who were withdrawn/early terminated 
â€¢ Subjects who have not met inclusion/exclusion criteria 
â€¢ Subjects who received excluded concomitant medications 
â€¢ Subjects who have major protocol deviations - all protocol deviations will be classified as major or minor 
under the discussion with Sponsor before database is locked. 
 
Additional criteria maybe added prior to unblinding of the study database.  
 
The Per Protocol Set will be used to perform the sensitivity analysis on the primary, the secondary, and 
the explor
atory efficacy endpoints. 
 
7.4 Safety Analysis Set 
 
The Safety Analysis Set will consist of all randomized subjects who received at least one dose of study 
medication and had any post-randomization safety data collected will be included in the evaluation of safety. 
Analyses of demographic and baseline characteristics, safety endpoints and summary of study medication 
administration will utilize this analysis set. 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 16 16 October 2017  8. INTERIM ANALYS IS 
 
No interim analyses are planned for this Phase 2 study. 
 
9. DATA SCREENING AND ACCPETANCE 
 
9.1 General Principles 
 
The objective of data screening is to assess the quantity, quality, and statistical characteristics of the data 
relative to the requirements of the planned analyses. The Bio-statistics associate (BSA) who is in charge of 
this study will check errors of raw data prior to the beginning of data analysis.  
 
9.2 Data Handling and Electronic Transfer of Data 
 
After database is locked, a raw data validated by using Microsoft Structured Query Language (MsSQL) will 
be directly accessed using SAS Open Database Connectivity ( ODBC ) Driver. The raw data needed for 
analysis will be transferred from Database Management System (DBMS) to standard folder to store the raw 
data on the server via SAS ODBC, and the analysis dataset will be created in â€žDATASETâ€Ÿ folder. The 
analysis dataset will be generated using SAS software version 9.4 according to analysis dataset specification 
created in accordance with this SAP. 
 
9.3 Handling of Missing and Incomplete Data 
 
If 
subjects either discontinues from the clinical trial or the outcome measurement at any point is missing post-
baseline, then the missing data will be imputed from the last measured outcome value using the Last 
Observation Carried Forward (LOCF) method. 
 
9.3.1 Missing and Incomplete Dates 
 
Missing or incomplete dates will be listed as it is in any listings. 
 
Incomplete start date of an adverse event or concomitant medication taken will be handled by following rule: 
 
Start Date  Missing  Imputation  Exception  
Adverse Event  
Concomitant Medication  
 
 Day 
 
 
 01 Default to Study Day 1 if an AE starts at the same 
year and month as Study Day 1 and the flag 
indicates that the AE started on or after the first 
dose on the AE CRF  
Day/Month  
 
 
 01JAN Default to Study Day 1 if an AE started at the 
same year as Study Day 1 and the flag indicates 
that the AE started on or after the first dose on the 
AE CRF 
Day/Month/Year  
 No Imputation   
 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 17 16 October 2017  9.3.2 Missing Baseline Evaluation 
 
Missing baseline will not be imputed. 
 
9.3.3 Missing Post-Baseline Evaluation 
 
Primary analysis of continuous efficacy endpoints will be analyzed based on observed data without 
imputation. 
 
In the sensitivity analysis of primary and the secondary efficacy endpoints, missing continuous efficacy 
endpoints will be handled using the LOCF method. 
 
In the LOCF method, post-baseline missing continuous endpoints will be imputed using the last observed 
value including baseline value. For example, if subject has all of the post-baseline values as missing, then all 
of the post-baseline values will be imputed using the observed baseline value. 
 
9.3.4 Handling of Repeated Laboratory Test Results 
 
Repeated laboratory test data will be handled after identifying the reason. If it is due to a test error, then the 
last value of the visit will be used, and if a clinical opinion is required, then the team will request the 
clinicianâ€Ÿs opinion and will decide what value to use. 
 
9.4 Handling of Early Termination  
 
In order to analyze and summarize the data consistently, the last visit performed for Early Termination will be 
mapped to their closest to scheduled visit within the analysis dataset. 
 
For example, if a subject completed efficacy measurement at Week 0, then the subject got early terminated 
from the study 4 weeks later and completed efficacy measurement, then the efficacy measurement for ET will 
be mapped to Week 4 visit.  
 
Example #1: 
 
Before: 
Week 0 ( 02FEB2017)  ET (02MAR2017) 
Efficacy Measurement â€“ Done  Efficacy Measurement â€“ Done  
 
After:  
Week 0 (02FEB2017)  Week 4 (02MAR2017) 
Efficacy Measurement â€“ Done  Efficacy Measurement â€“ Done  
Note: Week 2 to Week 12 have Â± 3 day visit window 
 
  
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 18 16 October 2017  Example #2: 
 
Before: 
Week 0 (02FEB2017)  ET (05MAR2017) 
Efficacy Measurement â€“ Done  Efficacy Measurement â€“ Done  
 
After:  
Week 0 (02FEB2017)  Week 4 (05MAR2017) 
Efficacy Measurement â€“ Done  Efficacy Measurement â€“ Done  
Note: Week 2 to Week 12 have Â± 3 day visit window 
 
For example, if a subject completed efficacy measurement at Weeks 0, 4, 8 then the subject got early 
terminated from the study 4 weeks later after Week 8 and completed efficacy measurement, and then the 
efficacy measurement for ET will be mapped to Week 12 visit.  
  
Example #3: 
 
Before: 
Week 0 ( 29MAR2017)  Week 4 (26APR2017)  Week 8 (24MAY2017)  ET (21JUN2017)  
Efficacy Measurement â€“ 
Done  Efficacy Measurement â€“ 
Done  Efficacy Measurement â€“ 
Done Efficacy Measurement â€“ 
Done 
 
After:  
Week 0 ( 29MAR2017)  Week 4 (26APR2017)  Week 8 (24MAY2017)  Week 12 (21JUN2017)  
Efficacy Measurement â€“ 
Done  Efficacy Measurement â€“ 
Done  Efficacy Measurement â€“ 
Done Efficacy Measurement â€“ 
Done 
Note: Week 2 to Week 12 have Â± 3 day visit window 
 
Each case will be discussed and decided with the study team and will be documented in the analysis dataset 
specification. 
 
9.5 Outliers Detection 
 
Histograms or raw data review will be examined to identify outliers in any of the continuous variables used in 
the analyses. Unexpected and/or unexplained values in categorical data will be identified by utilizing 
frequency tables. 
 
Outliers due to data entry errors will be corrected by the study team before the database lock. The validity of 
any questionable values or outliers will be confirmed. Outliers or any questionable values with confirmed 
validity will be included in the analyses. However, ad-hoc sensitivity analyses may be conducted to evaluate 
the influence of extreme values in the data.   If it is deemed necessary after the team reviews the output from 
the planned analyses after the database lock, post-hoc analyses excluding subjects with outliers may be 
performed. 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 19 16 October 2017  9.6 Bias Detection 
 
Randomization and blinding are performed for avoiding bias in this phase 2 study. Major protocol deviations 
will be listed and or/tabulated in the clinical study report (CSR). Any breaking of the blind for individual 
subjects prior to unblinding of the study will be documented in the CSR. The timing of and reasons for 
premature withdrawal from treatment and from study will be tabulated and /or listed. 
 
9.7 Distributional Characteristics 
 
Continuous endpoints of change from baseline value will be analyzed under normality assumption. If they 
deviate appreciably from normality, then appropriate non-parametric alternatives will be considered. 
 
9.8 Validation of Statistical Analyses 
 
The procedure for the validation of the analysis result is as follows: 
 
1) Self-check: The BSA in charge will check for oneself that the SAS program code, output, execution log, 
etc. are written correctly. 
2) Double programming and the review: The BSA in charge and other BSA will write SAS program code 
independently, and the Bio-statistics manager (BSM; Reviewer) will compare the outputs such as table, 
graph, listing that are printed by the SAS program code. 
3) Source code check: The BSM will check the written source code visually, and will check whether it is 
properly processed according to its purpose. 
4) Table/Graph: The BSM will check the values displayed in tables and graphs. 
5) Listing/Raw data: The BSM will check whether the raw data and listing are the same or not. 
 
10. STATISTICAL ANALYSES 
 
10.1 General Principles 
 
Statistical analysis will be conducted after database is locked and performed using SAS software version 9.4 
according to this SAP. If statistical analysis methods are changed, it will be described in the final clinical 
study report. 
 
Continuous variables will be summarized with means, standard deviations, medians, 25th & 75th percentiles, 
minimums, and maximums. Categorical variables will be summarized with counts and percentages. P-values 
less than 0.05 will be considered statistically significant. No adjustments for multiple comparison will be 
made to the result presented in this study because this is a phase 2 clinical trial and it is not formally powered 
with statistical algorithms. 
 
  
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 20 16 October 2017  10.2 Subject Disposition 
 
The disposition of all randomized patients will be tabulated by randomized treatment group. The numbers of 
all patients classified as follows will be summarized with count, percentage and flow chart by site and 
treatment group. 
 
â€¢ All patients who enrolled into the study 
â€¢ Patients who were randomized 
â€¢ Patients who were treated  
â€¢ Patients who were completed 
â€¢ Prematurely withdrawn  
â€¢ The reasons for premature withdraw al 
 
10.3 Protocol Deviations  
 
â€¢ All protocol deviations occurred during this study will be summarized by treatment group. Subjects who 
have protocol deviations will be categorized as follows; 
 
1) Subjects who have visits outside window 
2) Subjects who have not met inclusion criteria or met exclusion criteria but were entered into the study 
3) Subjects who received an excluded concomitant medications/treatment 
4) Subjects who have other protocol deviations 
 
â€¢ Individual patients with these protocol deviations will be listed by site. 
 
10.4 Demographic and Baseline Characteristics 
 
Demographic characteristics, medical history, medication history, extent of exposure, and efficacy variables 
at baseline will be summarized using descriptive statistics by randomized treatment group and overall study 
population using FAS and Safety Analysis Set. Continuous variables will be summarized with mean, standard 
deviation, median, 25th & 75th percentiles, minimum and maximum. Categorical variables will be summarized 
with count (number of subjects and/or number of events) and percentage. Because, in theory, the goal of 
randomization is to balance out the subject characteristics, statistical tests are not planned for these variables. 
 
10.4.1 Demographic Characteristics 
 
â€¢ Sex (Male, Female) 
â€¢ Age 
â€¢ Ethnicity (Hispanic, Non-Hispanic) 
â€¢ Race (Black or African American, Native Hawaiian or other Pacific Islander, Native American Indian or 
Native Alaskan, Asian, White, Other) 
â€¢ Height 
 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 21 16 October 2017  10.4.2 Medical History 
 
â€¢ Type of Diabetes (Type I Diabetes, Type II Diabetes, Gestational Diabetes) 
â€¢ Diabetes disease period 
â€¢ Past medical history status (Yes, No) and past medical history classified by System Organ Class (SOC) 
and Preferred Term (PT) according to MedDRA (Medical Dictionary for Regulatory Activities) version 
20.0. 
â€¢ Present medical history status (Yes, No) and present medical history classified by SOC and PT according 
to MedDRA version 20.0 
 
10.4.3 Concomitant Medications 
 
â€¢ Status (Yes, No) of concomitant medications and concomitant medications classified by Level1 and 
Level2 according to Anatomical Therapeutic Chemical (ATC) code WHODRUG version 2017 at V1 
(screening) 
 
10.4.4 Efficacy Variables at Baseline 
 
â€¢ HbA1c 
â€¢ Body Weight (BW) 
â€¢ FPG level 
â€¢ Waist Circumference 
â€¢ Mean value of postprandial (2 hours after dinner) blood glucose level 
â€¢ OGTT 
â€¢ ADDQoL questionnaire scores 
â€¢ Thyroid Function Test: TSH, T3, and T4 
â€¢ Serum parameters: zinc, insulin, adiponectin, C-peptide, leptin, and glucagon 
â€¢ Urine parameters: zinc, glucose, microalbumin, and copper 
â€¢ TAFGC 
â€¢ BMI  
 
10.5 Efficacy Analyses 
 
The analyses of efficacy endpoints will utilize EAS. Subjects will be analyzed according to their randomized 
treatment group regardless of the actual treatment received during the study. Per protocol analyses of the 
primary, secondary, and exploratory endpoints will utilize the Per Protocol Set. 
 
  
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 22 16 October 2017  Detailed primary analysis methods, sensitivity analyses are summarized in the table below. 
 
 
Endpoint s Primary Analysis and 
Analysis Method   
Sensitivity Analysis at Week 12  
Primary Endpoint s 
Change of HbA1c level from 
baseline at Week 12  
Change of BW from baseline at 
Week 12  1. EAS: Summary statistics by 
visit using observed data  
2. EAS: ANOVA model and 
Dunnett's test , and paired t -test 1. LOCF , EAS : Summary statistics 
and analyze using an ANOVA model  
and Dunnett's test , and paired t -test 
2. Per Protocol Set : Same as primary 
summary and analysis method at 
Week 12  
Secondary Endpoint s 
Change of FPG level from baseline  
at Week 12  1. EAS: Summary statistics by 
visit using observed data  
2. EAS: ANOVA model and 
Dunnett's test , and paired t -test 1. LOCF , EAS : Summary statistics 
and analyze using an ANOVA model  
and Dunnett's test , and paired t -test 
2. Per Protocol Set : Same as primary 
summary and analysis method at 
Week 12  
Proportion of subjects achieving 
HbA1c goal of  < 7.0% at Week 12  1. EAS: Summary statistics by 
visit using observed data  
2. EAS: Chi-square test  
 1. LOCF , EAS : Summary statistics 
and analyze using chi-square test  
2. Per Protocol Set : Same as primary 
summary and analysis method at 
Week 12  
Proportion of subjects achieving 
HbA1c goal of < 6.5% at Week 12  Same as above  Same as  above  
Change in waist circumference from 
baseline at Week 12  1. EAS: Summary statistics by 
visit using observed data  
2. EAS: ANOVA model and 
Dunnett's test , and paired t -test 1. LOCF , EAS : Summary statistics 
and analyze using an ANOVA model  
and Dunnett's  test, and paired t -test 
2. Per Protocol Set : Same as primary 
summary and analysis method at 
Week 12  
Change of postprandial (2 hours 
after dinner) blood glucose level 
from baseline at Week 12  Same as above  Same as above  
Change of OGTT from baseline at 
Week 12  Same as above  Same as above  
Change of score in ADDQoL 
questionnaire from baseline at  
Week 12  
 
 
 
 Same as above  Same as above  
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 23 16 October 2017   
Endpoint s Primary Analysis and 
Analysis Method   
Sensitivity Analysis at Week 12  
Exploratory Endpoints  
Change of following variables from 
baseline at Week 12:  
Thyroid Function Test : TSH, T3, 
and T4  
Serum Parameters : zinc, insulin, 
adiponectin, C-peptide, leptin, and     
glucagon  
Urine Parameters : zinc, glucose, 
microalbumin, and copper  
TAFGC  
BMI  1. EAS: Summary statistics by 
visit using observed data  
2. EAS: ANOVA model and 
Dunnett's test , and paired  t-test 
 1. Per Protocol Set : Same as primary 
summary and analysis method at 
Week 12  
 
10.5.1 Primary Efficacy Analyses 
 
â€¢ The change of HbA1c level from baseline at Week 12 will be summarized with mean, standard deviation, 
median, 25th & 75th percentiles, minimum, and maximum, overall and by each of the four groups, 
separately. To identify statistically significant difference in the change of HbA1c level from baseline at 
Week 12 between the four groups, one-way ANOVA will be performed. The tests between the 
experimental groups and the control group will be performed using Dunnett's test. If the change variables 
are markedly non-normally distributed then Kruskal-Wallis test and Wilcoxon rank-sum test will be used 
respectively. Specifically, all three experimental groups will be compared to the control group on the 
change: Dose A vs. D, B vs. D, and C vs. D. Also, to identify statistical significant difference between 
baseline and Week 12, one-sample t-test (paired t-test) or Wilcoxon signed-rank test will be performed 
within each of the four groups. 
 
â€¢ The change of BW from baseline at Week 12 will be summarized with mean, standard deviation, median , 
25th & 75th percentiles, minimum, and maximum, overall and by each of the four groups, separately. To 
identify statistically significant difference in the change of BW from baseline at Week 12 between the 
four groups, one-way ANOVA will be performed. The tests between the experimental groups and the 
control group will be performed using Dunnett's test. If the change variables are markedly non-normally 
distributed then Kruskal-Wallis test and Wilcoxon rank-sum test will be used respectively. Specifically, 
all three experimental groups will be compared to the control group on the change: Dose A vs. D, B vs. D, 
and C vs. D. Also, to identify statistical significant difference between baseline and Week 12, one-sample 
t-test (paired t-test) or Wilcoxon signed-rank test will be performed within each of the four groups. 
 
â€¢ Sensitiv
ity analysis described below will be performed for the primary endpoints at Week 12: 
 
1. Summary statistics and ANOVA model for continuous endpoints using imputed data by LOCF, EAS. 
2. Primary summary and analysis method based on Per Protocol Set. 
  
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 24 16 October 2017  10.5.2 Secondary Efficacy Analyses 
 
â€¢ The change of FPG level from baseline at Week 12 will be summarized with mean, standard deviation, 
median, 25th & 75th percentiles, minimum, and maximum, overall and by each of the four groups, 
separately. To identify statistically significant difference in the change of FPG level from baseline at 
Week 12 between the four groups, one-way ANOVA will be performed. The tests between the 
experimental groups and the control group will be performed using Dunnett's test. If the change variables 
are markedly non-normally distributed then Kruskal-Wallis test and Wilcoxon rank-sum test will be used 
respectively. Specifically, all three experimental groups will be compared to the control group on the 
change: Dose A vs. D, B vs. D, and C vs. D. Also, to identify statistical significant difference between 
baseline and Week 12, one-sample t-test (paired t-test) or Wilcoxon signed-rank test will be performed 
within each of the four groups. 
 
â€¢ The proportion of subjects achieving HbA1c goal of < 7.0% at Week 12 will be summarized with count 
and percentage, overall and by each of the four groups, separately. The proportion of subjects achieving 
HbA1c goal of < 7.0% at Week 12 will be compared for the experimental groups versus the control group 
using chi-square test method. In a case when the expected cell frequencies are less than 5 in >20%, 
Fisherâ€Ÿs exact test will be used. 
 
â€¢ The 
proportion of subjects achieving HbA1c goal of < 6.5% at Week 12 will be summarized with count 
and percentage, overall and by each of the four groups, separately. The proportion of subjects achieving 
HbA1c goal of < 6.5% at Week 12 will be compared for the experimental groups versus the control group 
using chi-square test method. In a case when the expected cell frequencies are less than 5 in >20% , 
Fisherâ€Ÿs exact test will be used. 
 
â€¢ The change in waist circumference from baseline at Week 12 will be summarized with mean, standard 
deviation, median, 25th & 75th percentiles, minimum , and maximum, overall and by each of the four 
groups, separately. To identify statistically significant difference in the change in waist circumference 
from baseline at Week 12 between the four groups, one-way ANOVA will be performed. The tests 
between the experimental groups and the control group will be performed using Dunnett's test. If the 
change variables are markedly non-normally distributed then Kruskal-Wallis test and Wilcoxon rank-sum 
test will be used respectively. Specifically, all three experimental groups will be compared to the control 
group on the change: Dose A vs. D, B vs. D, and C vs. D. Also, to identify statistical significant 
difference between baseline and Week 12, one-sample t-test (paired t-test) or Wilcoxon signed-rank test 
will be performed within each of the four groups. 
 
â€¢ The change of postprandial (2 hours after dinner) blood glucose level from baseline at Week 12 will be 
summarized with mean, standard deviation, median, 25th & 75th percentiles, minimum, and maximum, 
overall and by each of the four groups, separately. To identify statistically significant difference in the 
change of postprandial (2 hours after dinner) blood glucose level from baseline at Week 12 between the 
four groups, one-way ANOVA will be performed. The tests between the experimental groups and the 
control group will be performed using Dunnett's test. If the change variables are markedly non-normally 
distributed then Kruskal-Wallis test and Wilcoxon rank-sum test will be used respectively. Specifically, 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 25 16 October 2017  all three experimental groups will be compared to the control group on the change: Dose A vs. D, B vs. D, 
and C vs. D. Also, to identify statistical significant difference between baseline and Week 12, one-sample 
t-test (paired t-test) or Wilcoxon signed-rank test will be performed within each of the four groups. 
 
â€¢ The chang
e of OGTT from baseline at Week 12 will be summarized with mean, standard deviation, 
median, 25th & 75th percentiles, minimum, and maximum, overall and by each of the four groups, 
separately. To identify statistically significant difference in the change of OGTT from baseline at Week 
12 between the four groups, one-way ANOVA will be performed. The tests between the experimental 
groups and the control group will be performed using Dunnett's test. If the change variables are markedly 
non-normally distributed then Kruskal-Wallis test and Wilcoxon rank-sum test will be used respectively. 
Specifically, all three experimental groups will be compared to the control group on the change: Dose A 
vs. D, B vs. D, and C vs. D. Also, to identify statistical significant difference between baseline and Week 
12, one-sample t-test (paired t-test) or Wilcoxon signed-rank test will be performed within each of the 
four groups. 
 
â€¢ The change of score in ADDQoL questionnaire from baseline at Week 12 will be summarized with mean, 
standard deviation, median, 25th & 75th percentiles, minimum, and maximum, overall and by each of the 
four groups, separately. To identify statistically significant difference in the change of score in ADDQoL 
questionnaire from baseline at Week 12 between the four groups, one-way ANOVA will be performed. 
The tests between the experimental groups and the control group will be performed using Dunnett's test. 
If the change variables are markedly non-normally distributed then Kruskal-Wallis test and Wilcoxon 
rank-sum test will be used respectively. Specifically, all three experimental groups will be compared to 
the control group on the change: Dose A vs. D, B vs. D, and C vs. D. Also, to identify statistical 
significant difference between baseline and Week 12, one-sample t-test (paired t-test) or Wilcoxon 
signed-rank test will be performed within each of the four groups. 
 
â€¢ Sensitivity analysis described below will be performed for the secondary endpoints at Week 12: 
 
1. Summary statistics and ANOVA model for continuous endpoints using imputed data by LOCF, EAS. 
2. Primary summary and analysis method based on Per Protocol Set. 
 
10.5.3 Exploratory Efficacy Analyses 
 
The exploratory efficacy variables will be summarized with mean, standard deviation, median, 25th & 75th 
percentiles, minimum, and maximum, overall and by each of the four groups, separately. To identify 
statistically significant difference in the exploratory efficacy variables between the four groups, one-way 
ANOVA will be performed. The tests between the experimental groups and the control group will be 
performed using Dunnett's test. If the change variables are markedly non-normally distributed then Kruskal-
Wallis test and Wilcoxon rank-sum test will be used respectively. Specifically, all three experimental groups 
will be compared to the control group on the change : Dose A vs. D, B vs. D, and C vs. D. Also, to identify 
statistical significant difference between baseline and Week 12, one-sample t-test (paired t-test) or Wilcoxon 
signed-rank test will be performed within each of the four groups. 
 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 26 16 October 2017  â€¢ Thyroid Function Test: TSH, T3, and T4 
â€¢ Serum Parameters: zinc, insulin, adiponectin, C-peptide, leptin, and glucagon 
â€¢ Urine Parameters: zinc, glucose, microalbumin, and copper 
â€¢ TAFGC 
â€¢ BMI 
 
â€¢ Sensitivity analysis described below will be performed for the exploratory endpoints at Week 12: 
 
1. Primary summary and analysis method based on Per Protocol Set. 
 
10.6 Safety Analyses 
 
Safety analysis will be performed based on data of safety analysis set. Safety variables will be summarized 
with descriptive statistics, overall and by each of the four groups, separately. Continuous safety variables will 
be summarized with mean, standard deviation, median, 25th & 75th percentiles, minimum, and maximum. 
Categorical safety variables will be summarized with count and percentage.  
 
No statistical testing comparing treatment groups will be performed in the safety analyses. 
 
10.6.1 Adverse Events 
 
â€¢ All adverse events (AEs) in CRF will be classified by SOC and PT according to MedDRA version 20.0.  
 
â€¢ A treatment-emergent AE (TEAE) will be defined as an AE that began or worsened on or after the first 
treatment dose. AEs recorded prior to the first application of study treatment will be considered non-
treatment-emergent. AEs with insufficient date or time information to determine whether or not they were 
treatment-emergent will be considered treatment-emergent. 
 
â€¢ All reported AEs (treatment-emergent or not) will be listed. Only TEAEs will be summarized. 
 
(1) TEAEs will be summarized with the number of subjects who have AEs, incidence rate of AE s, and 
the number of AEs by categorizing as follows; 
â‘  AE/ADR* (Adverse event/ Adv erse drug reaction)  
*TEAEs which have the relationship to investigational product as 'Definite', 'Probable', and 
'Possible' are regarded as Drug-Related Adverse Events (ADR). 
â‘¡ SAE/SADR ( Serious adverse event/Serious  adverse drug reaction) 
 
(2) TEA
Es will also be summarized with the number of subjects who have AEs, incidence rate of AEs , 
the number of AEs, and its percentage by categorizing as follows. 
â‘  Outcome  
- Recovered or Resolved 
- Recovering or Resolving 
- Recovered or Resolved with Sequelae 
- Not Recovered or Not Resolved 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 27 16 October 2017  - Death Related to Adverse Event 
- Unknown 
â‘¡ Severity  
- Mild 
- Moderate 
- Severe 
â‘¢ Relationship to Investigational Product (IP) 
- Definite 
- Probable 
- Possible 
- Not Likely 
- Not Related 
â‘£ Action Taken Regarding IP 
- None 
- Reduced 
- Increased 
- Interrupted 
- Discontinued 
â‘¤ Treatment Required  
- Yes 
- No 
â‘¥ Seriousness  
- Is life-threatening 
- Requires in-patient hospitalization or prolongation of existing hospitalization 
- Results in persistent or significant disability or incapacity 
- Is a congenital anomaly or birth defect 
- Is an important medical event 
- Results in death 
 
â€¢ Episodes of hypoglycemia and hyperglycemia (V2-V8) 
 
(1) Hypoglycemia occurred after previous visit will be summarized with the number of subjects who are 
occurred episode and the count of episode by each visit separately. 
 
(2) Hyperglycemia occurred after previous visit will be summarized with the number of subjects who are 
occurred episode and the count of episode by each visit separately. 
 
(3) Sponsor defined Hypoglycemia (blood glucose â‰¤ 70 mg/dL) occurred after previous visit will be 
summarized with the number of subjects who are occurred episode and the count of episode by each 
visit separately. 
 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 28 16 October 2017  (4) Sponsor defined Hyperglycemia (blood glucose â‰¥ 180 mg/dL) occurred after previous visit will be 
summarized with the number of subjects who are occurred episode and the count of episode by each 
visit separately. 
 
10.6.2 Laboratory Test Results 
 
â€¢ Laboratory tests are: 
 
- Hematology: RBC, WBC, Neutrophil count, Lymphocyte count, Monocyte count, Eosinophil count, 
Basophil count, Hematocrit, Hemoglobin, Platelets, MCH, MCHC, MCV, and RDW 
 
- Chemistry: ALT, Albumin, Alkaline phosphatase, AST, Total Bilirubin, BUN, Calcium, Bicarbonate, 
Chloride, Creatinine, Potassium, Total Protein, Sodium, and Glucose 
 
â€¢ Laboratory test results will be collected at V1, V2, V4, V6, and V8. These variables will be summarized 
with mean, standard deviation, median, 25th & 75th percentiles, minimum, and maximum by each 
treatment group and by each visit separately.  
 
â€¢ Normality of laboratory test results [Normal, Abnormal (CS, NCS) ] will be summarized with count 
(number of subjects) and percentage by each treatment group and by each visit separately.  
 
10.6.3 Vital Signs 
 
â€¢ Vital signs [Sitting blood pressure (systolic, diastolic), Heart rate, Breathing, and Temperature] will be 
collected at V1, V2, V3, V4, V5, V6, V7, V8, and V9. These variables will be summarized with mean, 
standard deviation, median, 25th & 75th percentiles, minimum and maximum by each treatment group and 
by each visit separately.  
 
10.6.4 Physical Examination and 12-lead ECG 
 
â€¢ Result of physical examination (General Appearance, Head-Ears-Eyes-Nose-Throat, Neck, Heart, Lungs, 
Abdomen, Lymph Nodes, Genitourinary, Extremities, Neurological, Skin, Musculoskeletal, and Others) 
will be collected at V1, V2, V4, V6, and V8. These results (Normal, Abnormal) will be summarized with 
count (number of subjects) and percentage by each treatment group and by each visit separately.  
 
â€¢ Result of 12-lead ECG will be collected at V1 and V8. This result [Normal, Abnormal (CS, NCS)] will be 
summarized with count and percentage by each treatment group and by each visit separately. 
 
10.6.5 Exposure to IP 
 
â€¢ Study drug exposure day will be summarized with mean, standard deviation, median, 25th & 75th 
percentiles, minimum, and maximum by each treatment group and by each visit separately.  
 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 29 16 October 2017  â€¢ Number of Capsules taken will be summarized with mean, standard deviation, median, 25th & 75th 
percentiles, minimum, and maximum by each treatment group and by each visit separately.  
 
â€¢ Compliance will be summarized with mean, standard deviation, median, 25th & 75th percentiles, minimum, 
and maximum by each treatment group and by each visit separately.  
 
10.6.6 Concomitant Medication Use 
 
â€¢ Concomitant medications status (Yes, No) collected at V2-V9 will be summarized with count and 
percentage by each treatment group separately. Concomitant medications classified by Level1 and Level2 
according to ATC code WHODRUG version 2017 will be also summarized. 
 
10.7 CHP Concentration Analysis 
 
Levels of CHP assessed in blood for a subset of subjects if there are residual serum and/or plasma after 
completion of protocol-required tests will be summarized with mean, standard deviation, median, 25th & 75th 
percentiles, minimum, and maximum.  
 
No statistical tests are planned for these data. 
 
10.8 Subgroup Analysi s  
 
To explore the robustness of efficacy signal, primary, secondary, and exploratory efficacy endpoints may also 
be analyzed separately by excluding potential outliers.  
 
10.9 Post-hoc Analysis  
 
To understand the data better for future study design, post-hoc analyses may also be performed separately. 
 
11. REPORTING CONVENTIONS 
 
All results of analysis will be reported in table or figure format to assist the understanding for the study results. 
The descriptive summary statistics for continuous variables will be presented in the number of subjects (n), 
mean, standard deviation, median, 25th & 75th percentiles, minimum, and maximum and the descriptive 
summary statistics for categorical variables will be given as frequencies, percentages.  
 
The number of decimal places presented for each statistic will be as follows: 
 
â€¢ Mean, median, 25th percentile, 75th percentile: one more than the number of decimal places recorded x  
â€¢ Standar
d deviation: two more than the number of decimal places recorded x  
â€¢ Minimum and maximum: equal to the number of decimal places recorded  
â€¢ Percentage: reported to one decimal place using rounding off 
â€¢ P-value: reported to four decimal places and if p-values smaller than 0.0001 will be written as â€ž<0.0001â€Ÿ. 
 
All dates will be displayed in DDMMMYYYY format (for example, 11JAN2015). 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 30 16 October 2017  Data for individual subjects will be presented in data listings.  
 
12. AD
JUSTED STATISTICAL ANALYSIS METHOD 
 
Not applicable. 
 
13. CHANGES IN THE STATISTICAL ANALYSIS FROM THE PROTOCOL 
 
Section 4.3  Two exploratory endpoints have been added. The endpoints are as follows: 
 
â€¢ Change in TAFGC from baseline at Week 12 
â€¢ Change in BMI from baseline at Week 12 
 
Section 6  New definitions have been added for Baseline, Study Day. The definitions are as follows: 
 
Baseline  is defined as the last non-missing measurement taken on Week 0.  
 
Study day 1  is defined as the first IP dose date. For subjects who are randomized but not dosed after 
randomization, the study day 1 is defined as the date of randomization. 
 
Study day  is defined as the number of days from study day 1. 
 
Before study day 1:  study day = (date of interest â€“ date of study day 1) 
On or a
fter study day 1:  study day = (date of interest â€“ date of study day 1) + 1 
 
Therefore, the day prior to study day 1 is -1. 
 
Section 7.1  Full Analysis Set has been added. The definition of FAS is as follows:  
 
The Full Analysis Set (FAS) includes all subjects who were randomized in the study. Subjects will be 
analyzed according to their randomized treatment, regardless of the treatment received. Tabulations of subject 
enrollment by site, analysis subsets, demographic and baseline characteristics including diabetes disease, past 
and present medical history, concomitant medication, subject disposition, and major protocol deviations will 
utilize this analysis set. 
 
Section 7.2  Efficacy Analysis Set has been replaced with Intent- to-Treat Set. The updated definition of EAS 
is as follows:  
 
The Efficacy Analysis Set (EAS) will be used to carry out the efficacy analyses of efficacy endpoints, which 
is a subset of the FAS consisting of subjects who received at least one dose of study medication and who had 
baseline and any post-baseline efficacy data. Subjects will be analyzed according to their randomized 
treatment, regardless of the treatment received. Analyses for efficacy endpoints will utilize this analysis set.  
 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 31 16 October 2017  Section 9.3  Handling of missing, incomple te data, and repeated laboratory test data has been added in detail. 
The details are as follows: 
 
Only participants whose efficacy variable were measured least once after baseline. If participants either 
discontinues from the clinical trial or the outcome measurement at any point is missing, then the missing data 
will be imputed from the last measured outcome value using the Last Observation Carried Forward (LOCF) 
method. 
 
If repeated laboratory test data collected is due to a test error, then the last value of the visit will be used, and 
if a clinical opinion is required, then it will be used one value determined under discussion. 
 
No imputation methods are planned for safety analysis. 
 
Section 9.4  Handling of Early Termination has been added in detail. The details are as follows:  
 
In order to analyze and summarize the data consistently, the last visit performed for Early Termination will be 
mapped to their closest to scheduled visit within the analysis dataset. See Section 9.4 of this SAP to see more 
examples in detail. 
 
Section 10.5  Efficacy Analyses. The detailed primary analysis methods, sensitivity analyses are added and 
summarized in the table below. 
 
Endpoint  Primary Analysis and Analysis 
Method Sensitivity Analysis at Week 12  
Primary Endpoints  
Chang e of HbA1c level from 
baseline at Week 12  
Change of BW from baseline at 
Week 12  1. EAS: Summary statistics by visit 
using observed data  
2. EAS: ANOVA model and 
Dunnett's test, and paired t -test 1. LOCF , EAS : Summary statistics 
and analyze using an ANOVA 
model and Dunnett's test , and 
paired t -test 
2. Per Protocol Set : Same as 
primary summary and analysis 
method at Week 12  
Secondary Endpoints  
Change of FPG level from baseline  
at Week 12  1. EAS: Summary statistics by visit 
using observed data  
2. EAS: ANOVA model and 
Dunnett's test , and paired t -test 1. LOCF , EAS : Summary statistics 
and analyze using an ANOVA 
model and Dunnett's test , and 
paired  t-test 
2. Per Protocol Set : Same as 
primary summary and analysis 
method at Week 12  
Proportion of subjects achieving 
HbA1c goal of < 7.0% at Week 12  1. EAS: Summary statistics by visit 
using observed data  
2. EAS: Chi-square test  1. LOCF , EAS : Summary statistics 
and analyze using chi -square test  
2. Per Protocol Set : Same as 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 32 16 October 2017  Endpoint  Primary Analysis and Analysis 
Method Sensitivity Analysis at Week 12  
 primary summary and analysis 
method at Week 12  
Proportion of subjects achieving 
HbA1c goal of < 6.5% at Week 12  Same as above  Same as above  
Change in waist circumference 
from baseline at Week 12  1. EAS: Summary statistics by visit 
using observed data  
2. EAS: ANOVA model and 
Dunnett's test , and paired t -test 1. LOCF , EAS : Summary statistics 
and analyze using an ANOVA 
model and Dunnett's test , and 
paired t -test 
2. Per Protocol Set: Same as 
primary summary and analysis 
method at Week 12  
Change of postprandial (2 hours 
after dinner) blood glucose level 
from baseline at Week 12  Same as above  Same as above  
Change of OGTT from baseline at 
Week 12 Same as above  Same as above  
Change  of score in ADDQoL 
questionnaire from baseline at 
Week 12 Same as above  Same as above  
Exploratory Endpoints  
Change of following variables 
from baseline at Week 12:  
Thyroid Function Test : TSH, T3, 
and T4 
Serum Parameters : zinc, insulin, 
adiponectin, C-peptide, leptin, and 
glucagon 
Urine Parameters : zinc, glucose, 
microalbumin, and copper  
TAFGC  
BMI  1. EAS: Summary statistics by visit 
using observed data  
2. EAS: ANOVA model and 
Dunnett's test , and paired t -test 
 1. Per Protocol Set : Same as 
primary summary and analysis 
method at Week 12  
 
Section 10.6.1  New definition of Hypoglycemia and Hypoglycemia have been added in detail. The details are 
as follows:  
 
(1) Sponsor defined Hypoglycemia (blood glucose â‰¤ 70 mg/dL) occurred after previous visit will be 
summarized with the number of subjects who are occurred episode and the count of episode by each 
visit separately. 
 
NovMetaPharma Co., Ltd. 
NMP- CYZ -P2-001  
Statistical Analysis Plan                                                                                                                     Version 1.2 
 
 
 
CONFIDENTIAL Page 33 16 October 2017  (2) Sponsor defined Hyperglycemia (blood glucose â‰¥ 180 mg/dL) occurred after previous visit will be 
summarized with the number of subjects who are occurred episode and the count of episode by each 
visit separately. 
 
Section 10.8  Subgroup Analysis has been added. The details are as follows: 
 
To explore the robustness of efficacy signal, primary, secondary, and exploratory efficacy endpoints may also 
be analyzed separately by excluding potential outliers.  
 
Section 10.9  Post-hoc Analysis has been added. The details are as follows: 
 
To understand the data better for future study design, post-hoc analyses may also be performed separately. 
 
14. REFERENCES 
 
Clinical Study Protocol â€œA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to 
Evaluate the Efficacy and Safety of Cyclo-Z in Patients with Obese Type 2 Diabetesâ€, Version 2.4, December 
9, 2016  
 